Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Multiple Myeloma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Breast Neoplasms 2Vomiting 1Uterine Cervical Neoplasms 1Trigger Finger Disorder 1Sarcoma, Alveolar Soft Part 1Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Pain 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoplasm Metastasis 1Nausea 1Mucositis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Mast-Cell 1Leukemia, Hairy Cell 1

Interventions

Rituximab 208Cyclophosphamide 167Etoposide 83Prednisone 79Vincristine 77Doxorubicin 76Peripheral Blood Stem Cell Transplantation 61Filgrastim 55Cytarabine 47fludarabine phosphate 46Radiotherapy 43Lenalidomide 41Mycophenolic Acid 40Tacrolimus 36Methotrexate 35Melphalan 35Busulfan 35Gemcitabine 32Carmustine 32Cyclosporine 31Whole-Body Irradiation 29Ifosfamide 28Antilymphocyte Serum 26zanubrutinib 25polatuzumab vedotin 25Dexamethasone 23Methylprednisolone 22ibritumomab tiuxetan 20Carboplatin 20Oxaliplatin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Large B-Cell, Diffuse × Acetaminophen × Clear all
NCT04660799 2023-10-12

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche

Phase 2 Completed
50 enrolled 25 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Stanford University

Phase 2 Terminated
3 enrolled 13 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡